Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Lunsekimig by Sanofi for Asthma: Likelihood of Approval
Lunsekimig is under clinical development by Sanofi and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Data Insights
Risk adjusted net present value: What is the current valuation of Sanofi's Lunsekimig?
Lunsekimig is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Asthma. According to Globaldata, it...